Orbimed Advisors Llc Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 29,063 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $44.58, for a total value of $1,295,628.54. Following the completion of the sale, the director owned 3,530,702 shares of the company’s stock, valued at $157,398,695.16. The trade was a 0.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Orbimed Advisors Llc also recently made the following trade(s):

• On Monday, February 2nd, Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.57, for a total transaction of $84,237.30.
• On Wednesday, December 24th, Orbimed Advisors Llc sold 33,356 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.55, for a total transaction of $1,486,009.80.
• On Friday, December 19th, Orbimed Advisors Llc sold 875 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $38,928.75.
• On Thursday, December 18th, Orbimed Advisors Llc sold 100 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $4,449.00.
• On Wednesday, December 17th, Orbimed Advisors Llc sold 900 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.50, for a total transaction of $40,050.00.
• On Wednesday, November 26th, Orbimed Advisors Llc sold 1,600 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total transaction of $71,184.00.
• On Tuesday, November 25th, Orbimed Advisors Llc sold 11,890 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.60, for a total transaction of $530,294.00.
• On Monday, November 24th, Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.54, for a total value of $4,212,726.82.

Sionna Therapeutics Trading Down 14.7%

NASDAQ SION opened at $35.25 on Friday. Sionna Therapeutics, Inc. has a 1-year low of $7.26 and a 1-year high of $45.00. The stock has a 50-day moving average of $41.23 and a 200-day moving average of $32.82. The firm has a market cap of $1.57 billion and a PE ratio of -7.24.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Key Stories Impacting Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Analyst consensus and price targets provide upside context — brokers’ average target (~$45.43) and several buy/strong‑buy reports give the stock valuation support versus current levels, suggesting analysts expect further recovery over time. Read More.
• Neutral Sentiment: Upcoming investor event could be a catalyst — management will present at the Guggenheim Emerging Outlook: Biotech Summit on Feb. 11; the presentation may supply pipeline updates or Q&A that could move the stock depending on tone and new details. Read More.
• Negative Sentiment: Insider and institutional selling produced near‑term downward pressure — Director Peter A. Thompson and Orbimed Advisors LLC disclosed sales of 29,063 shares (plus an additional 1,890-share trim) at ~ $44.57–$44.58. Although the sales represent small percentages of large holdings, they add liquidity and can prompt stop‑loss or momentum selling around those price levels. Read More. Read More.

Hedge Funds Weigh In On Sionna Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. purchased a new stake in Sionna Therapeutics in the third quarter worth about $30,000. BNP Paribas Financial Markets purchased a new position in shares of Sionna Therapeutics during the 2nd quarter worth approximately $31,000. GF Fund Management CO. LTD. bought a new position in shares of Sionna Therapeutics in the 4th quarter worth approximately $36,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Sionna Therapeutics in the 2nd quarter valued at approximately $45,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Sionna Therapeutics during the fourth quarter valued at approximately $89,000.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Lifesci Capital began coverage on shares of Sionna Therapeutics in a report on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 price target for the company. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada restated an “underperform” rating and set a $24.00 price target on shares of Sionna Therapeutics in a report on Monday, December 1st. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $53.00 price target on shares of Sionna Therapeutics in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $45.43.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.